International Congress Munich 2014


PG17 Lung cancer: the issue with the tissue

Postgraduate Course
Chairs: P. Schnabel (Meckesheim, Germany), N. Peled (Tel Aviv, Israel)
Aims: Targeted therapy has become the standard treatment for patients with advanced lung cancer. Thus, routine molecular staging is needed. What tissues are needed, how can we obtain enough tissue, and how do we interpret the data? Based on the published literature, different issues will be discussed with a special focus on daily problems.

HERMES SYLLABUS LINKS
ADULT: Module E.1 Treatment modalities and prevention measures

Educational Material

Handout PG17
Open
How to access educational materials from mobile devices
What do we need from our patients? - the clinician's point of view
C. Dooms (Leuven, Belgium)
WebcastSlide presentationPDF journal article, handout or slidesMultimedia files
WebcastSlide presentationPDF journal article, handout or slidesMultimedia files
What tissues do we obtain from our patients? - the pathologist's point of view
P. Schnabel (Meckesheim, Germany)
PDF journal article, handout or slides
PDF journal article, handout or slides
How do we interpret the sample data?
A. Cortot (Lille, France)
WebcastSlide presentationPDF journal article, handout or slidesMultimedia files
WebcastSlide presentationPDF journal article, handout or slidesMultimedia files
How should tumour sample analysis be applied to patient management?
T. Berghmans (Brussels, Belgium)
WebcastSlide presentationPDF journal article, handout or slidesMultimedia files
WebcastSlide presentationPDF journal article, handout or slidesMultimedia files